Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

Dr. Sarah Sammons highlights various first-line treatment approaches that combine CDK4/6 inhibitors with endocrine therapy as treatment for HR+/HER2- metastatic breast cancer.

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

A brief review of the full spectrum of risk factors that impact the likelihood of interstitial lung disease.

Comprehensive insight on the symptomology of interstitial lung disease, followed by tools and methods that can aid in accurate diagnosis.

Joyce A. O’Shaughnessy, MD, provides an overview of interstitial lung disease, considering both causes and possible risk factors.

Take-home messages regarding the optimal identification and management of ILD in breast cancer through the lens of multidisciplinary care.

Drawing from personal experience, experts provide practical advice on identifying and treating interstitial lung disease in patients with breast cancer during the era of COVID-19.

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.

Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.

Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.

Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.